Clinical Research Management announced it has been awarded a new, 5-year, $97MM research support contract titled Support for Military Medical Research for the Soldier (SMMRS) to be performed at the Walter Reed Army Institute of Research (WRAIR). The United States Army Medical Research Acquisition Activity (USAMRAA) awarded the contract to ClinicalRM. USAMRAA is both the contracting element of the US Army Medical Research and Materiel Command (USAMRMC) and the provider of support to the Command headquarters and its worldwide network of laboratories and medical logistics organizations.
Through the course of the contract, ClincalRM will provide support for WRAIR’s goal of improving both national and international efforts to develop drugs, vaccines and associated products to address diseases of strategic interest to the United States Military and to develop products to enhance warfighter resilience, and reduce and mitigate the impact of brain injury and combat stress.
“We are very proud of the support our company currently provides to WRAIR which makes this award especially important. It is a testament to the value we bring to critical research that supports the warfighter and our country,” said Victoria Tifft, founder and CEO of ClinicalRM.
For 18 years, ClinicalRM has proven itself as a trusted partner to the US Armed Forces providing basic and applied research, clinical trials, and regulatory approval for a wide variety of agents. The SMMRS contract start date is July 1, 2011.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.